FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366333656> ?p ?o ?g. }

• W4366333656 endingPage "e006070" @default.
• W4366333656 startingPage "e006070" @default.
• W4366333656 abstract "Background Mismatch repair deficiency (dMMR) is a well-recognized biomarker for response to immune checkpoint blockade (ICB). Strategies to convert MMR-proficient (pMMR) to dMMR phenotype with the goal of sensitizing tumors to ICB are highly sought. The combination of bromodomain containing 4 (BRD4) inhibition and ICB provides a promising antitumor effect. However, the mechanisms underlying remain unknown. Here, we identify that BRD4 inhibition induces a persistent dMMR phenotype in cancers. Methods We confirmed the correlation between BRD4 and mismatch repair (MMR) by the bioinformatic analysis on The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium data, and the statistical analysis on immunohistochemistry (IHC) scores of ovarian cancer specimens. The MMR genes (MLH1,MSH2,MSH6,PMS2) were measured by quantitative reverse transcription PCR, western blot, and IHC. The MMR status was confirmed by whole exome sequencing, RNA sequencing, MMR assay and hypoxanthine-guanine phosphoribosyl transferase gene mutation assay. The BRD4i AZD5153 resistant models were induced both in vitro and in vivo. The transcriptional effects of BRD4 on MMR genes were investigated by chromatin immunoprecipitation among cell lines and data from the Cistrome Data Browser. The therapeutic response to ICB was testified in vivo. The tumor immune microenvironment markers, such as CD4, CD8, TIM-3, FOXP3, were measured by flow cytometry. Results We identified the positive correlation between BRD4 and MMR genes in transcriptional and translational aspects. Also, the inhibition of BRD4 transcriptionally reduced MMR genes expression, resulting in dMMR status and elevated mutation loads. Furthermore, prolonged exposure to AZD5153 promoted a persistent dMMR signature both in vitro and in vivo, enhancing tumor immunogenicity, and increased sensitivity to α-programmed death ligand-1 therapy despite the acquired drug resistance. Conclusions We demonstrated that BRD4 inhibition suppressed expression of genes critical to MMR, dampened MMR, and increased dMMR mutation signatures both in vitro and in vivo, sensitizing pMMR tumors to ICB. Importantly, even in BRD4 inhibitors (BRD4i)-resistant tumor models, the effects of BRD4i on MMR function were maintained rendering tumors sensitive to ICB. Together, these data identified a strategy to induce dMMR in pMMR tumors and further, indicated that BRD4i sensitive and resistant tumors could benefit from immunotherapy." @default.
• W4366333656 created "2023-04-20" @default.
• W4366333656 creator A5002042528 @default.
• W4366333656 creator A5005221518 @default.
• W4366333656 creator A5006421021 @default.
• W4366333656 creator A5008366921 @default.
• W4366333656 creator A5012022141 @default.
• W4366333656 creator A5013167986 @default.
• W4366333656 creator A5015584107 @default.
• W4366333656 creator A5018324533 @default.
• W4366333656 creator A5030141706 @default.
• W4366333656 creator A5032931020 @default.
• W4366333656 creator A5034030001 @default.
• W4366333656 creator A5035780050 @default.
• W4366333656 creator A5041470064 @default.
• W4366333656 creator A5042530731 @default.
• W4366333656 creator A5045067652 @default.
• W4366333656 creator A5056078581 @default.
• W4366333656 creator A5066716873 @default.
• W4366333656 creator A5073228982 @default.
• W4366333656 creator A5075138338 @default.
• W4366333656 creator A5076256227 @default.
• W4366333656 creator A5083907893 @default.
• W4366333656 date "2023-04-01" @default.
• W4366333656 modified "2023-09-26" @default.
• W4366333656 title "BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors" @default.
• W4366333656 cites W1534408084 @default.
• W4366333656 cites W1940241680 @default.
• W4366333656 cites W1988626905 @default.
• W4366333656 cites W1998228484 @default.
• W4366333656 cites W2000596495 @default.
• W4366333656 cites W2060484997 @default.
• W4366333656 cites W2070918875 @default.
• W4366333656 cites W2109790992 @default.
• W4366333656 cites W2118428599 @default.
• W4366333656 cites W2118952409 @default.
• W4366333656 cites W2120018526 @default.
• W4366333656 cites W2138601221 @default.
• W4366333656 cites W2141298492 @default.
• W4366333656 cites W2146290346 @default.
• W4366333656 cites W2154181923 @default.
• W4366333656 cites W2287918349 @default.
• W4366333656 cites W2516657620 @default.
• W4366333656 cites W2544405043 @default.
• W4366333656 cites W2618278879 @default.
• W4366333656 cites W2622499649 @default.
• W4366333656 cites W2770647635 @default.
• W4366333656 cites W2791440239 @default.
• W4366333656 cites W2888408613 @default.
• W4366333656 cites W2900679912 @default.
• W4366333656 cites W2915944698 @default.
• W4366333656 cites W2932374721 @default.
• W4366333656 cites W2947159010 @default.
• W4366333656 cites W2987148655 @default.
• W4366333656 cites W3008777649 @default.
• W4366333656 cites W3009897923 @default.
• W4366333656 cites W3012375969 @default.
• W4366333656 cites W3022016772 @default.
• W4366333656 cites W3025750971 @default.
• W4366333656 cites W3031120515 @default.
• W4366333656 cites W3043480372 @default.
• W4366333656 cites W3134244175 @default.
• W4366333656 cites W3209660117 @default.
• W4366333656 doi "https://doi.org/10.1136/jitc-2022-006070" @default.
• W4366333656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37072347" @default.
• W4366333656 hasPublicationYear "2023" @default.
• W4366333656 type Work @default.
• W4366333656 citedByCount "0" @default.
• W4366333656 crossrefType "journal-article" @default.
• W4366333656 hasAuthorship W4366333656A5002042528 @default.
• W4366333656 hasAuthorship W4366333656A5005221518 @default.
• W4366333656 hasAuthorship W4366333656A5006421021 @default.
• W4366333656 hasAuthorship W4366333656A5008366921 @default.
• W4366333656 hasAuthorship W4366333656A5012022141 @default.
• W4366333656 hasAuthorship W4366333656A5013167986 @default.
• W4366333656 hasAuthorship W4366333656A5015584107 @default.
• W4366333656 hasAuthorship W4366333656A5018324533 @default.
• W4366333656 hasAuthorship W4366333656A5030141706 @default.
• W4366333656 hasAuthorship W4366333656A5032931020 @default.
• W4366333656 hasAuthorship W4366333656A5034030001 @default.
• W4366333656 hasAuthorship W4366333656A5035780050 @default.
• W4366333656 hasAuthorship W4366333656A5041470064 @default.
• W4366333656 hasAuthorship W4366333656A5042530731 @default.
• W4366333656 hasAuthorship W4366333656A5045067652 @default.
• W4366333656 hasAuthorship W4366333656A5056078581 @default.
• W4366333656 hasAuthorship W4366333656A5066716873 @default.
• W4366333656 hasAuthorship W4366333656A5073228982 @default.
• W4366333656 hasAuthorship W4366333656A5075138338 @default.
• W4366333656 hasAuthorship W4366333656A5076256227 @default.
• W4366333656 hasAuthorship W4366333656A5083907893 @default.
• W4366333656 hasBestOaLocation W43663336561 @default.
• W4366333656 hasConcept C104317684 @default.
• W4366333656 hasConcept C111425858 @default.
• W4366333656 hasConcept C134935766 @default.
• W4366333656 hasConcept C2776674815 @default.
• W4366333656 hasConcept C2777701055 @default.
• W4366333656 hasConcept C2779115348 @default.
• W4366333656 hasConcept C2780851360 @default.

• next